Which medications in the drug class Anticoagulants are used in the treatment of Deep Venous Thrombosis (DVT)?

Updated: Jun 05, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print
Answer

Anticoagulants

These agents prevent recurrent or ongoing thrombolytic occlusion of the vertebrobasilar circulation.

Rivaroxaban (Xarelto)

Rivaroxaban is an oral factor Xa inhibitor that inhibits platelet activation by selectively blocking the active site of factor Xa without requiring a cofactor (eg, antithrombin III) for activity. It is indicated for a variety of treatment and prophylaxis VTE indications including the following:

Risk reduction of stroke and systemic embolism in nonvalvular atrial fibrillation

Treatment of DVT

Treatment of PE

Reduction in risk of recurrent DVT and/or PE

Prophylaxis of DVT following hip or knee replacement surgery

Prophylaxis of VTE in acutely ill medical patients at risk for thromboembolic complications owing to restricted mobility (and who are not at high risk of bleeding)

Risk reduction of major CV events with CAD or PAD

Apixaban (Eliquis)

Apixaban is an oral factor Xa inhibitor that inhibits platelet activation by selectively and reversibly blocking the active site of factor Xa without requiring a cofactor (eg, antithrombin III) for activity. It inhibits free and clot-bound factor Xa, and prothrombinase activity; no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. It is indicated for prophylaxis of deep venous thrombosis (DVT) or pulmonary embolism (PE) in adults undergoing knee or hip replacement surgery. It is also indicated for treatment of DVT and PE and for prevention of recurrence (following the initial 6 months of the initial treatment).

Dabigatran (Pradaxa)

Dabigatran inhibits free and clot-bound thrombin and thrombin-induced platelet aggregation. It is indicated for the prevention of stroke and systemic embolism associated with nonvalvular atrial fibrillation (NVAF). This agent is also indicated for the prevention and treatment of deep venous thrombosis (DVT) or pulmonary embolism (PE).

Edoxaban (Savaysa)

Edoxaban is indicated to reduce the risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation (NVAF). 

Betrixaban (Bevyxxa)

Betrixaban is indicated for the prophylaxis of venous thromboembolism (VTE) in adults hospitalized for acute medical illness who are at risk for thromboembolic complications owing to moderate or severe restricted mobility and other risk factors that may cause VTE.

Fondaparinux sodium (Arixtra)

Fondaparinux sodium is a synthetic anticoagulant that works by inhibiting factor Xa, a key component involved in blood clotting. It provides a highly predictable response and has a bioavailability of 100%. The drug has a rapid onset of action and a half-life of 14-16 hours, allowing for sustained antithrombotic activity over 24-hour period. Fondaparinux sodium does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation.

Heparin

Heparin augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. It does not actively lyse but is able to inhibit further thrombogenesis. Heparin prevents reaccumulation of a clot after a spontaneous fibrinolysis.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!